Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICHE: Neoadjuvant Immune Checkpoint Inhibition in Early-stage Colon Cancer
NCT03026140Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2017
- Primary completion
- Mar 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab, celecoxib oral solution, adakitug, relatlimab in colon cancer, sponsored by Netherlands Cancer Institute. Started Mar 2017; status: recruiting.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03026140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03026140.